Physician profile
Kumuda Ranjan
NPI 1033459961
$678.71
in general payments reported to CMS, 2019-2025
16 companies · $96.24 in 2025
The $96.24 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $73.46 · 2021: $70.01 · 2022: $47.44 · 2023: $117 · 2024: $132 · 2025: $96.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $345.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $104.30 | 2022-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $97.39 | 2024-2025 | |
| Dynavax Technologies Corporation | $74.59 | 2023-2024 | Heplisav-B |
| Pfizer INC. | $68.00 | 2019-2020 | |
| Novo Nordisk INC | $63.93 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $50.77 | 2019-2021 | |
| Amgen INC. | $34.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $29.97 | 2019-2024 | Airsupra |
| Abbvie INC. | $28.97 | 2021-2023 | |
| Inspire Medical Systems, INC. | $26.80 | 2025 | Inspire |
| Lilly USA, LLC | $23.48 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $19.73 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.48 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.22 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $13.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumuda Ranjan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.